CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology company developing genetic medicines for people with rare and common diseases, announced the promotion of Phillip Samayoa, Ph .D., to Chief Strategy Officer. dr Samayoa has led Generation Bio’s strategy, corporate and portfolio development since joining the company in 2017, most recently as Senior Vice President.
“Phillip has been instrumental in establishing a holistic platform development strategy that will enable its application to multiple genetic medicine modalities,” said Geoff McDonough, MD, President and Chief Executive Officer of Generation Bio. “In this new role, Phillip will lead corporate strategy, business development and discovery research, enabling the integration of these important strategic activities.”
“We are leaders in the field of non-viral DNA therapeutics and targeted delivery of lipid nanoparticles, and I look forward to expanding the opportunity space for Generation Bio’s unique technologies – closed DNA, rapid enzymatic synthesis and cell-directed lipid nanoparticles – to expand further. said Dr. Samayoa. “I look forward to continuing to work with this amazing team to push the boundaries of our platform and maximize its potential benefits for patients.”
Phillip Samayoa co-founded Generation Bio as a Director at Atlas Venture, where he focused on genetic medicines and building novel platform therapeutics companies. During his time at Atlas, Dr. Samayoa also co-founded Dyne Therapeutics. Previously, he was Director of the MRL Ventures Fund at Merck, where he helped set up the strategic venture fund and led investments in early stage companies such as Alector, Translate Bio and Spero Therapeutics. Before Merck, Dr. Samayoa Associate at Flagship Pioneering, where he helped build several startups including Codiak BioSciences and Indigo Ag. dr Samayoa graduated from MIT with two Bachelor of Science degrees in Bioengineering and Physics and earned his Ph.D. in Systems Biology from UC San Diego, where he was an NSF Graduate Research Fellow.
About Generation Bio
Generation Bio develops genetic medicines to provide durable, reusable treatments for people living with rare and common diseases. The company’s non-viral genetic medicine platform contains a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-directed lipid nanoparticle delivery system or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES) to produce ceDNA. The platform is designed to enable multi-year shelf life from a single dose, deliver large genetic payloads, including multiple genes, to specific tissues, and allow for titration and re-dosing to adjust or expand expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to expand the reach of genetic medicine to more people with more diseases around the world.
Visit www.generationbio.com for more information.
Any statements in this press release regarding future expectations, plans and prospects for the Company, including statements about our strategic plans or goals, our technology platform, our research and clinical development plans and preclinical data and other statements containing the words “believe”, ” “expects”, “plans”, “expects” and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those described in such forward-looking statements as a result of a number of important factors, including: uncertainties, inherent in the identification and development of product candidates, including conducting research activities, initiating and completing pre-clinical studies and clinical trials, and clinical development of the Company’s product candidates; uncertainties regarding the availability and timing of results from pre-clinical studies and clinical studies; whether results from previous preclinical studies predict the results of later preclinical studies and clinical studies; uncertainties related to the RES manufacturing process; expectations of regulatory approvals to conduct studies or commercialize products; challenges in the manufacture of genetic medicine products; whether the company has sufficient cash resources to fund the company’s operating expenses and capital expenditure requirements for the anticipated period; the impact of the COVID-19 pandemic on the Company’s business and operations; and the other risks and uncertainties discussed in the “Risk Factors” section of our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in subsequent filings by the Company with the Securities and Exchange Commission can make. In addition, the forward-looking statements contained in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. Although the Company may elect to update these forward-looking statements at any time in the future, the Company expressly disclaims any obligation to do so. These forward-looking statements should not be construed as representing the Company’s views at any time after the date on which they are made.
Investors and media contact